share_log

Adaptimmune Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results and reaffirmed guidance.

Benzinga ·  Aug 5, 2022 02:55
Adaptimmune Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results and reaffirmed guidance.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment